Stock A092730 NEOPHARM CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings NeoPharm CO., LTD.

Equities

A092730

KR7092730001

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-09 pm EDT 		5-day change 1st Jan Change
30,000 KRW +1.52% Intraday chart for NeoPharm CO., LTD. +5.26% +16.05%
2023 NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2019 NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 10.73 for the current year.
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Historically, the company has been releasing figures that are above expectations.

Ratings chart - Surperformance

Sector: Personal Products

1st Jan change Capi. Investor Rating ESG Refinitiv
NEOPHARM CO., LTD. Stock NeoPharm CO., LTD.
+16.05% 171M -
L'ORÉAL Stock L'Oréal
+0.40% 260B
B-
KAO CORPORATION Stock Kao Corporation
+16.33% 19.96B
B+
GALDERMA GROUP AG Stock Galderma Group AG
0.00% 19.45B - -
SHISEIDO COMPANY, LIMITED Stock Shiseido Company, Limited
+19.21% 12.92B
A-
AMOREPACIFIC CORPORATION Stock Amorepacific Corporation
+21.45% 7.85B
B+
PROYA COSMETICS CO.,LTD. Stock Proya Cosmetics Co.,Ltd.
+9.98% 5.95B
B
NATURA &CO HOLDING S.A. Stock Natura &Co Holding S.A.
-11.49% 3.9B
B+
KOSÉ CORPORATION Stock KOSÉ Corporation
-1.37% 3.82B
B
INTER PARFUMS, INC. Stock Inter Parfums, Inc.
-21.44% 3.68B
C-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. A092730 Stock
  4. Ratings NeoPharm CO., LTD.